title: Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
abstract: Hypogonadal men have lower prostate volumes and serum prostate-specific antigen (PSA) levels than age-matched controls. When present, prostate cancer in hypogonadal men is more aggressive than in eugonadal men, and given the lack of specificity of PSA for diagnosing prostate cancer, a more accurate test would be desirable in hypogonadal men. Once testosterone-replacement therapy is started in hypogonadal men, PSA levels should be measured regularly; however, there is often an initial rise 3-6 months after starting treatment. A rise of >0.5 ng/mL within this time requires further investigation.
authors.affiliation: Department of Urology, The Prostate Centre, London, UK. duncangould@hotmail.com
authors.forename: Duncan C
authors.initials: DC
authors.lastname: Gould
authors.forename: Mark R
authors.initials: MR
authors.lastname: Feneley
authors.forename: Roger S
authors.initials: RS
authors.lastname: Kirby
mesh_terms: D000368:Aged; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D013739:Testosterone / Q000009:adverse effects*
chemical_list: D013739:Testosterone; D017430:Prostate-Specific Antigen